2024-12-10 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance vs. S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading pharmaceutical company.  The provided data shows that MRK's cumulative return (70.55%) significantly lagged behind the S&P 500's cumulative return (120.73%) over the analyzed period.  The difference is -50.2%, placing it in the 11.9th percentile of its historical range of performance relative to the S&P 500.  This indicates underperformance compared to the broader market.  The provided Alpha values consistently show negative returns (-0.1) compared to the benchmark, further confirming underperformance.

**2. Recent Price Movement:**

* **Closing Price:** $103.79
* **5-day moving average:** $102.73
* **20-day moving average:** $100.19
* **60-day moving average:** $106.28

The price is slightly above the 5 and 20-day moving averages, suggesting short-term upward momentum. However, it's below the 60-day moving average, indicating a potential recent pullback from a higher price point. The difference between the closing price (103.82) and the last market price is negligible.  There is no evidence of a sharp price increase or decrease.

**3. Technical Indicators and Expected Return:**

* **RSI:** 73.28  (Approaching overbought territory)
* **PPO:** 0.79 (Positive, indicating upward momentum)
* **20-day Relative Strength Change:** +4.2% (Short-term upward trend)
* **Expected Return:** 0.0% (This suggests no expected outperformance relative to the S&P 500 over the long term, based on the provided data.  Long-term projections should not rely solely on this single data point.)


**4. Recent Earnings Analysis:**

The provided earnings data reveals some inconsistencies (duplicate entries for 2024-11-06).  However, based on the unique entries:

* **Revenue:** Shows some fluctuation, with a slight increase overall from Q1 2023 to Q3 2024.  There is no clear consistent growth trend.
* **EPS:** Exhibits significant variability.  The EPS for Q2 2024 was substantially higher than the surrounding quarters.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue shows moderate growth with some fluctuations. Profit margins are generally high but have slightly decreased in recent quarters.
* **Capital and Profitability:** Equity has seen growth, however the Return on Equity (ROE) is highly variable, showing a significant negative ROE in Q4 2023, followed by higher positive ROEs in subsequent quarters.  This suggests volatility in profitability.

**6. News and Recent Issues:**

No recent (within the last two days) earnings news, market outlook, or analyst opinions are provided. This section requires additional information.

**7. Overall Analysis:**

MRK has shown underperformance compared to the S&P 500 over the given period. While some short-term positive technical indicators are present (PPO, 20-day relative strength change), the RSI suggests the stock may be nearing overbought territory.  Recent earnings have been inconsistent, with significant fluctuations in both revenue and EPS. The financial information reveals variability in profitability. Further analysis, including information on recent news and analyst opinions, is required for a more comprehensive assessment.  The lack of consistent positive trends in earnings and the negative Alpha raise concerns about MRK's long-term outlook relative to the market.  The 0% expected return further highlights the need for cautious consideration.


**8. Disclaimer:** This analysis is based solely on the limited data provided.  It does not constitute financial advice.  Independent research and consultation with a financial professional are recommended before making any investment decisions.
